Literature DB >> 16304368

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Oliver G Ottmann1, Barbara Wassmann.   

Abstract

Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL. Until recently, conventional chemotherapy programs that have been effective in other precursor B-cell ALL cases have been unable to cure patients with this diagnosis. Allogeneic stem cell transplantation early in first remission has been the recommended therapy. The availability of imatinib mesylate and other tyrosine kinase inhibitors and small molecules that affect the BCR/ABL signaling pathways may be changing the treatment paradigm and the prognosis for these patients. The results from clinical trials using imatinib in the frontline setting and in relapsed patients as well as preliminary experience treating imatinib-resistant Ph(+) ALL will be described.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304368     DOI： 10.1182/asheducation-2005.1.118

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  14 in total

1.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors:  A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

2.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.

Authors:  V Mühlbacher; T Haferlach; W Kern; M Zenger; S Schnittger; C Haferlach
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

4.  Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.

Authors:  Ahmad Hanif; Eunice S Wang; James E Thompson; Jeffrey I Baron; Mark D Walsh; Elizabeth A Griffiths
Journal:  Leuk Lymphoma       Date:  2017-12-18

Review 5.  Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Ryuzo Ohno
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 3.952

Review 6.  Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Ryuzo Ohno
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 7.  Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Sarah A Cross; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  IRF-4 functions as a tumor suppressor in early B-cell development.

Authors:  Jaime Acquaviva; Xiaoren Chen; Ruibao Ren
Journal:  Blood       Date:  2008-08-19       Impact factor: 22.113

9.  Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Authors:  I Iacobucci; A Ferrarini; M Sazzini; E Giacomelli; A Lonetti; L Xumerle; A Ferrari; C Papayannidis; G Malerba; D Luiselli; A Boattini; P Garagnani; A Vitale; S Soverini; F Pane; M Baccarani; M Delledonne; G Martinelli
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

Review 10.  Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.

Authors:  Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.